LSE - Delayed Quote GBp

MaxCyte, Inc. (MXCT.L)

212.20

-2.80

(-1.30%)

As of 8:26:19 AM GMT+1. Market Open.

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p

GlobeNewswire 19 days ago

MXCT
+1.39%
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)

MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 20 days ago

MXCT
+1.39%
With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

Key Insights Institutions' substantial holdings in MaxCyte implies that they have significant influence over the...

Simply Wall St. 20 days ago

MXCT
+1.39%
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 21 days ago

MXCT
+1.39%
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 24 days ago

MXCT
+1.39%
MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

MaxCyte Inc (MXCT) showcases strong core revenue growth and strategic acquisitions despite facing revenue declines and macroeconomic pressures.

GuruFocus.com last month

MXCT
+1.39%
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance. Fourth Quarter and Full Year Highlights Total revenue of $8.7 million in the fourth quarter of 2024,

GlobeNewswire last month

MXCT
+1.39%
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseasesROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-ba

GlobeNewswire 2 months ago

MXCT
+1.39%
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2024 after the U.S. market close on Tuesday, March 11th, 2025. Company management will host a conference call to discuss financial re

GlobeNewswire 2 months ago

MXCT
+1.39%
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies. This strategic acquisition strengthens MaxCyte’s ability to serve ex vivo and in vivo cell and gene

GlobeNewswire 2 months ago

MXCT
+1.39%
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...

Simply Wall St. 2 months ago

MXCT
+1.39%
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy

MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

MXCT
+1.39%
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?

While MaxCyte, Inc. ( LON:MXCT ) might not have the largest market cap around , it saw a significant share price rise...

Simply Wall St. 3 months ago

MXCT
+1.39%
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Unaudited Fourth Quarter and Full Year 2024 Results Core revenue in the fourth quarter is expe

GlobeNewswire 3 months ago

MXCT
+1.39%
MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price

Key Insights MaxCyte's estimated fair value is UK£5.59 based on 2 Stage Free Cash Flow to Equity MaxCyte's UK£3.24...

Simply Wall St. 3 months ago

MXCT
+1.39%
MaxCyte Announces Retirement of Board Member Art Mandell

ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxC

GlobeNewswire 4 months ago

MXCT
+1.39%
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This “bottom-up” review focused on optimizing ne

GlobeNewswire 4 months ago

MXCT
+1.39%
This MaxCyte Insider Increased Their Holding In The Last Year

Looking at MaxCyte, Inc.'s ( LON:MXCT ) insider transactions over the last year, we can see that insiders were net...

Simply Wall St. 5 months ago

MXCT
+1.39%
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projectsROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has rem

GlobeNewswire 5 months ago

MXCT
+1.39%
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...

MaxCyte Inc (MXCT) reports a 23% increase in core revenue and maintains a robust cash position, despite a decline in gross margin and drug discovery revenue.

GuruFocus.com 5 months ago

MXCT
+1.39%

Performance Overview

Return	MXCT.L	FTSE 100 (^FTSE)
YTD	-34.51%	+2.95%
1-Year	-28.07%	+3.28%
3-Year	-52.31%	+11.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MaxCyte, Inc. (MXCT.L)

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame

All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy

What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price

MaxCyte Announces Retirement of Board Member Art Mandell

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

This MaxCyte Insider Increased Their Holding In The Last Year

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...

Performance Overview